"CAMP" combination chemotherapy for unresectable non-oat cell bronchogenic carcinoma.
Experience with camp chemotherapy of 84 unresectable non-oat cell lung cancer patients is described. Fourteen (27%) of 51 patients with measurable lesions responded (3 CR, 11 PR) for a median response duration of 5 months with a range of 1 to 19+ months. Median survival of responders was 370 days, but response was not independent of performance status. Survival of patients without measurable lesions was less favorable than that of even nonresponders, suggesting prediction of response to CAMP by site of metastasis. Preliminary results of a randomized prospective trial of the CAMP combination versus CCNU as a single agent for patients with good performance status fail to show a difference in survival.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012075:Remission, Spontaneous; D013997:Time Factors
D000970:Antineoplastic Agents; D011344:Procarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate